Microbot Medical Reaches 50% Enrollment In Pivotal Clinical Trial For LIBERTY Endovascular Robotic Surgical System, Expects Full Enrollment And 510(k) FDA Submission By End Of 2024
Portfolio Pulse from Benzinga Newsdesk
Microbot Medical has achieved 50% enrollment in its pivotal clinical trial for the LIBERTY Endovascular Robotic Surgical System. The company anticipates full enrollment and a 510(k) FDA submission by the end of 2024.
September 17, 2024 | 12:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Microbot Medical has reached a significant milestone with 50% enrollment in its clinical trial for the LIBERTY system. The company plans to complete enrollment and submit for FDA approval by the end of 2024, which could positively impact its stock.
The achievement of 50% enrollment in the pivotal trial is a key milestone for Microbot Medical, indicating progress towards regulatory approval. The anticipated FDA submission by the end of 2024 suggests a positive development trajectory, likely boosting investor confidence and potentially increasing the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100